Your AI-Trained Oncology Knowledge Connection!
This rapid readout highlights results from a global Phase III trial evaluating giredestrant as adjuvant therapy for estrogen receptor–positive, HER2-negative early breast cancer. The study demonstrated a clinically meaningful improvement in invasive disease-free survival compared with standard endocrine therapy, with a favorable and comparable safety profile.
Arielle Medford, MD, highlights the results of the LEADER study, examining how ctDNA-based molecular residual disease testing can enable early detection of recurrence and inform treatment decisions in hormone receptor–positive, HER2-negative early breast cancer.
David Gerber, MD discusses treating Lambert-Eaton Myasthenic Syndrome in patients with small-cell lung cancer based on updated guidelines.
This presentation reviews final overall survival and long-term outcomes from the phase 3 EMBARK trial evaluating enzalutamide-based treatment strategies in patients with high-risk biochemically recurrent prostate cancer.
This video presents an updated analysis from the BENEFIT (IFM 20205) study, led by Professor Xavier Leleu, focusing on sustained measurable residual disease (MRD) negativity in patients with newly diagnosed multiple myeloma. Following the primary results published in Nature Medicine in 2024, this update examines MRD negativity over time using next-generation sequencing at 12, 18, and 24 months after treatment initiation. The discussion emphasizes that sustained MRD negativity—rather than a single timepoint or complete response rate—is the most clinically meaningful endpoint. Results show that quadruplet-based regimens achieve higher and more durable MRD negativity compared with triplet-based therapies. The video also explores outcomes in key biological subgroups, including patients with t(11;14) translocation, who demonstrate slower and lower rates of MRD negativity. Overall, the findings support the growing role of sustained MRD negativity as a critical endpoint to guide long-term treatment strategies in multiple myeloma.
An expert discusses interim safety findings from a phase 2 randomized study evaluating axatilimab in combination with ruxolitinib for patients with newly diagnosed chronic graft-versus-host disease, presented by Amandeep Salhotra, MD, of City of Hope National Medical Center.
Dr. Lorenzo Falchi presents primary phase 3 EPCORE FL-1 results showing that epcoritamab plus rituximab and lenalidomide significantly improves efficacy outcomes vs rituximab and lenalidomide alone in relapsed/refractory follicular lymphoma.
Four-year follow-up results from the Phase 3 CheckMate 9DW trial show that nivolumab plus ipilimumab continues to provide sustained overall survival and durable response benefits versus lenvatinib or sorafenib as first-line therapy for unresectable hepatocellular carcinoma. The combination demonstrated higher long-term survival rates and a higher complete response rate, with no new safety signals reported.
In this real-world retrospective study of patients with CLL/SLL treated at UCSF, outcomes with next-generation BTK inhibitors zanubrutinib and acalabrutinib were compared using adjusted analyses of time to next treatment and overall survival. Despite patients receiving zanubrutinib having more high-risk features and comorbidities, zanubrutinib was associated with a lower risk of starting subsequent therapy and a trend toward improved survival compared with acalabrutinib.
The RRO highlights that isatuximab combined with RVd as induction therapy produced deep and rapid responses in transplant-eligible patients with newly diagnosed multiple myeloma. The regimen was generally well tolerated with a favorable safety profile, and early molecular responses were observed in a meaningful proportion of patients.
Ryan Jacobs, MD discusses incidence of cardiac-related deaths among patients aged ≥65 years with B-cell malignancies treated with ibrutinib.
Leyla Shune MD, discusses Safety analysis of axatilimab in patients with chronic graft-versus-host disease in an expanded access program.
Discover the latest insights on Revumenib's real-world effectiveness in treating acute myeloid leukemia, presented at ASH 2025.
Emily S. Ruiz, MD, MPH, FAAD discusses efficacy and safety of cosibelimab in advanced cutaneous squamous cell carcinoma: Results from a pivotal open-label study with a median follow-up of ≥2 years.
Using data from the ALPINE trial, this analysis demonstrates that worsening patient-reported symptoms, particularly fatigue, insomnia, and nausea/vomiting, is significantly associated with increased risk of disease progression in patients with relapsed/refractory CLL/SLL.
This video details patient-reported outcomes from the DESTINY-Breast09 Phase 3 trial, comparing first-line treatments T-DXd + pertuzumab versus THP (taxane-based therapy) for HER2+ advanced/metastatic breast cancer.
Michael Wang, M.D. discusses Sonrotoclax (BGB-11417) monotherapy in patients with R/R MCL previously treated with a BTK inhibitor: results from a phase 1/2 study
Tracy I. George, MD discusses the effect of Bezuclastinib on the pathobiology of mastocytosis: changes in BM mast cells, Tryptase, and KIT p.D816V variant allele frequency from the pivotal summit trial
Constantine S. Tam, MD discusses long-term results of patients receiving Zanubrutinib in the Phase 3 ALPINE study confirm sustained benefit of Zanubrutinib in patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: Up to 6 years of follow-up with the long-term extension.
Constantine S. Tam, MD discusses frontline treatment of Sonrotoclax (BGB-11417) + Zanubrutinib for CLL/SLL demonstrates high uMRD rates with favorable tolerability: Updated data from BGB-11417-101, an ongoing phase 1/1b study.
Constantine S. Tam, MD, presents a modeled analysis estimating the number needed to treat (NNT) to prevent one progression or death when using zanubrutinib versus other covalent Bruton tyrosine kinase inhibitors (BTKis) in patients with high-risk relapsed/refractory chronic lymphocytic leukemia (R/R CLL).
Brian M. Shuch, MD, discusses the impact of 89Zr-girentuximab PET/CT versus conventional imaging on clinical decision making in patients with indeterminate renal masses (ZIRCON-X).
Thomas Powles, MBBS, MRCP, MD discusses IMvigor011: a Phase 3 trial of circulating tumour (ct)DNA-guided adjuvant atezolizumab vs placebo in muscle-invasive bladder cancer.
Priya Rastogi, MD discusses MonarchE: primary overall survival results of adjuvant Abemaciclib plus Endocrine therapy For HR+, HER2-, high-risk early breast cancer.
Thomas Hutson, DO, PharmD, PhD, FACP presents the latest findings from the CLEAR trial on lenvatinib + pembrolizumab vs sunitinib in patients with advanced renal cell carcinoma with or without bone metastases.
The presentation highlights results from the OptimUM-01 study evaluating darovasertib + crizotinib as first-line treatment for metastatic uveal melanoma, showing improved median overall survival (21.1 months) and higher response rates compared with historical standard therapies. The combination demonstrated a manageable safety profile, supporting its continued evaluation in the ongoing registrational OptimUM-02 trial.